Soleus Capital Management L.P. Makes New $28.94 Million Investment in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Soleus Capital Management L.P. purchased a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,276,000 shares of the life sciences company's stock, valued at approximately $28,940,000. Integra LifeSciences accounts for approximately 1.8% of Soleus Capital Management L.P.'s portfolio, making the stock its 17th biggest holding. Soleus Capital Management L.P. owned 1.65% of Integra LifeSciences as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Integra LifeSciences in the 4th quarter valued at $8,967,000. Principal Financial Group Inc. grew its stake in Integra LifeSciences by 5.5% in the 4th quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company's stock valued at $9,603,000 after acquiring an additional 22,000 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in Integra LifeSciences by 7.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock valued at $312,000 after acquiring an additional 913 shares during the period. Nisa Investment Advisors LLC grew its stake in Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after acquiring an additional 2,800 shares during the period. Finally, Northern Trust Corp grew its stake in Integra LifeSciences by 9.9% in the 4th quarter. Northern Trust Corp now owns 892,425 shares of the life sciences company's stock valued at $20,240,000 after acquiring an additional 80,090 shares during the period. Institutional investors and hedge funds own 84.78% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Wells Fargo & Company lowered their target price on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. JMP Securities dropped their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. JPMorgan Chase & Co. dropped their target price on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Finally, Truist Financial dropped their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a report on Friday, April 11th. Four analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $18.63.

Integra LifeSciences Trading Down 2.8%

Shares of IART traded down $0.36 during mid-day trading on Friday, reaching $12.30. The stock had a trading volume of 989,046 shares, compared to its average volume of 1,042,440. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a 52-week low of $11.60 and a 52-week high of $32.66. The business's fifty day moving average is $17.03 and its 200 day moving average is $21.38. The firm has a market cap of $955.86 million, a price-to-earnings ratio of -136.65, a P/E/G ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The firm had revenue of $382.65 million during the quarter, compared to analysts' expectations of $381.17 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company's revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.55 EPS. On average, sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.